Rescue Therapy for Helicobacter Pylori Eradication
Study Details
Study Description
Brief Summary
Tetracycline and metronidazole based quadruple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. This study aims to evaluate the efficacy and safety of the minocycline and metronidazole based bismuth quadruple therapy in the rescue treatment of helicobacter pylori infection.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Tetracycline Bismuth Quadruple Therapy Esomeprazole 20mg bid Bismuth Potassium Citrate 300mg bid Tetracycline 500mg qid Metronidazole 400mg qid |
Drug: Esomeprazole
Proton pump inhibitor
Drug: Bismuth Potassium Citrate
Gastric mucosal protective drug with anti-H. pylori effect
Drug: Tetracycline,Metronidazole
Antibiotics for H. pylori eradication
|
Experimental: Minocycline Bismuth Quadruple Therapy Esomeprazole 20mg bid Bismuth Potassium Citrate 300mg bid Minocycline 100mg bid Metronidazole 400mg qid |
Drug: Esomeprazole
Proton pump inhibitor
Drug: Bismuth Potassium Citrate
Gastric mucosal protective drug with anti-H. pylori effect
Drug: Minocycline,Metronidazole
Antibiotics for H. pylori eradication
|
Outcome Measures
Primary Outcome Measures
- Helicobacter pylori eradication rate [Six weeks after completion of therapy]
Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was defined as negative result from urea breath test (<4‰) (4‰ as the cutoff value).
Secondary Outcome Measures
- Rate of adverse effects [Within 7 days after completion of therapy]
The subjects were asked to grade the severity of adverse events according to their influence on daily activities, experienced as "mild" (transient and well tolerated), "moderate" (causing discomfort and partially interfering with daily activities), or "severe" (causing considerable interference with daily activities)
- Compliance rate [Within 7 days after completion of therapy]
Compliance was defined as poor when they had taken less than 80% of the total medication
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ability and willingness to participate in the study and to sign and give informed consent
-
Confirmed H. pylori infection and with previous treatment experience
Exclusion Criteria:
-
Less than 18 years old
-
With previous gastric surgery
-
Major systemic diseases
-
Pregnancy or lactation
-
Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Renji Hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai | Shanghai | China | 200127 |
Sponsors and Collaborators
- Shanghai Jiao Tong University School of Medicine
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- rjkls2019013